ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IBIO vs GANX // 10Y YIELD & FRED MACRO BETA

iBio Inc. (NASDAQ) VS. Gain Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IBIO 2 — GANX 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBIO VS. GANX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IBIO GANX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 77.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 34.0 +6.20 IBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $52.3M $51.9M $384.5K IBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IBIO REV GANX REV IBIO GROSS % GANX GROSS % IBIO FCF GANX FCF
FY 2025 $400.0K $0 — — -$15.3M -$18.5M
FY 2024 $225.0K $0 — — -$18.8M -$18.9M
FY 2023 $0 $55.2K — — -$30.4M -$18.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBIO // BETA —
GANX // BETA —